Manzo Pharmaceuticals(OTC) MNZO

Manzo Pharmaceuticals, Inc. is a specialized drug company focused on the discovery and development of proprietary and generic medical treatments. The company is actively working on Lacto-Freedom, a patented probiotic aimed at aiding individuals with lactose intolerance, and is also developing a natural solution for infant colic.

Products and Services

• Lacto-Freedom: A patented probiotic for lactose intolerance
• Natural solution for infant colic
• Research and development of additional medical therapies

Growth Outlook

• Recent quarterly revenue reached $60,000, indicating market interest
• Gross profit margin of 33.83% shows potential for profitability
• Continued investment in R&D to expand product offerings

Financial Highlights

• Trailing twelve months (TTM) revenue of $60,000 reflects growth potential
• Net income of $7,261 in the latest quarter demonstrates operational progress
• Cash flow coverage ratio of 4.58 indicates strong liquidity management

Manzo Pharmaceuticals, Inc. operates in the pharmaceutical sector with a focus on innovative solutions for common health issues. The company’s flagship product, Lacto-Freedom, addresses a significant market need for lactose intolerance treatments, which affects a large portion of the population. The recent quarterly performance shows a positive trend, with revenue growth and a healthy gross profit margin, suggesting that the company is on a path toward sustainable profitability. The strong cash flow coverage ratio further indicates effective financial management, positioning the company favorably for future growth. As the organization continues to invest in research and development, it aims to expand its product line and enhance its market presence.